← Leaderboards
Michel Benjamin Chonchol
University Of Colorado Denver
$9,752,858
Attributed
$15,998,469
Total exposure
13
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,277,362 · 14
By mechanism
R01$15,719,007 · 8
U2C$527,798 · 2
M01$30,557 · 4
Top collaborators
- Berenice Yolande Gitomer13 shared
- Kristen Lynn Nowak5 shared
- Liran Shlush5 shared
- Myles S Wolf5 shared
- Stephen L Seliger3 shared
- Anna E Beaudin1 shared
- Anna P Malykhina1 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Dana Dabelea$57,991,262
- Marian J. Rewers$53,889,410
- Victoria A Catenacci$13,159,123
- Nancy F Krebs$16,070,384
- Daniel Holland Bessesen$13,106,302
Others in their field
Top investigators on “Insight”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- James Dennis Neaton · Northwestern University$283,212,546
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$278,513,775
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$200,435,757
Research focus
InsightCardiovascular DiseasesChronic Kidney FailureAdultLinkEventKidney DiseasesRisk FactorsKidneyCardiovascular SystemClinical TrialsHypertensionCardiovascular Disorder RiskPathogenesisCessation Of LifeRenal FunctionResourcesCause Of DeathParticipantCohortHigh RiskEnd Stage Renal FailureDisease ProgressionMagnetic Resonance Imaging
Grant awards (42)
Inspiratory muscle strength training for lowering systolic blood pressure in midlife and older adults with chronic kidney disease$557,848
R01 · FY2025 · DK · contact PI
Kidney Stone Disease In ADPKD$500,750
R01 · FY2025 · DK · contact PI
Clonal hematopoiesis, mild cognitive impairment and kidney function decline$318,452
R01 · FY2025 · AG · contact PI
Mountain States Advancement in Research, Supportive Networking and Career Development (ASCEND)$278,893
U2C · FY2025 · DK · contact PI
Clonal hematopoiesis, mild cognitive impairment and kidney function decline$259,061
R01 · FY2025 · AG · contact PI
Mountain States Advancement in Research, Supportive Networking and Career Development (ASCEND)$248,905
U2C · FY2025 · DK · contact PI
Clonal hematopoiesis, mild cognitive impairment and kidney function decline$592,058
R01 · FY2024 · AG · contact PI
Inspiratory muscle strength training for lowering systolic blood pressure in midlife and older adults with chronic kidney disease$535,533
R01 · FY2024 · DK · contact PI
Kidney Stone Disease In ADPKD$491,228
R01 · FY2024 · DK · contact PI
Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease$283,693
R01 · FY2024 · DK · contact PI
Clonal hematopoiesis, mild cognitive impairment and kidney function decline$602,674
R01 · FY2023 · AG · contact PI
Inspiratory muscle strength training for lowering systolic blood pressure in midlife and older adults with chronic kidney disease$557,848
R01 · FY2023 · DK · contact PI
Kidney Stone Disease In ADPKD$453,195
R01 · FY2023 · DK · contact PI
Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD.$444,410
R01 · FY2023 · DK · contact PI
Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD$360,060
R01 · FY2023 · DK · contact PI
Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease$288,208
R01 · FY2023 · DK · contact PI
Clonal hematopoiesis, mild cognitive impairment and kidney function decline$624,094
R01 · FY2022 · AG · contact PI
Inspiratory muscle strength training for lowering systolic blood pressure in midlife and older adults with chronic kidney disease$557,848
R01 · FY2022 · DK · contact PI
Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD.$444,410
R01 · FY2022 · DK · contact PI
Kidney Stone Disease In ADPKD$436,789
R01 · FY2022 · DK · contact PI
Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease$302,408
R01 · FY2022 · DK · contact PI
Inspiratory muscle strength training for lowering systolic blood pressure in midlife and older adults with chronic kidney disease$594,865
R01 · FY2021 · DK · contact PI
Kidney Stone Disease In ADPKD$471,571
R01 · FY2021 · DK · contact PI
Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD.$444,410
R01 · FY2021 · DK · contact PI
Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD.$450,004
R01 · FY2020 · DK · contact PI
Nicotinamide riboside supplementation for treating arterial stiffness and elevated systolic blood pressure in patients with moderate to severe CKD.$466,566
R01 · FY2019 · DK · contact PI
FGF-23 and clinical outcomes in ADPKD patients$344,584
R01 · FY2016 · DK · contact PI
FGF-23 and clinical outcomes in ADPKD patients$479,326
R01 · FY2015 · DK · contact PI
Mineralocorticoid Antagonism and Endothelial Dysfunction$337,940
R01 · FY2015 · DK · contact PI
FGF-23 and clinical outcomes in ADPKD patients$485,928
R01 · FY2014 · DK · contact PI
Mineralocorticoid Antagonism and Endothelial Dysfunction$336,853
R01 · FY2014 · DK · contact PI
FGF-23 and clinical outcomes in ADPKD patients$454,586
R01 · FY2013 · DK · contact PI
Mineralocorticoid Antagonism and Endothelial Dysfunction$335,947
R01 · FY2013 · DK · contact PI
FGF-23 and clinical outcomes in ADPKD patients$524,846
R01 · FY2012 · DK · contact PI
Vitamin D and Clinical Outcomes in Chronic Hemodialysis Patients$321,889
R01 · FY2012 · DK · contact PI
Vitamin D and Clinical Outcomes in Chronic Hemodialysis Patients$321,889
R01 · FY2011 · DK · contact PI
Vitamin D and Clinical Outcomes in Chronic Hemodialysis Patients$361,130
R01 · FY2010 · DK · contact PI
Vitamin D and Clinical Outcomes in Chronic Hemodialysis Patients$376,106
R01 · FY2009 · DK · contact PI
CORONARYARTERYCALCIFICATIONS INHEMODIALYSISPTS W/SECONDARYHYPERPARATHYROIDISM$1,463
M01 · FY2008 · RR · contact PI
CORONARYARTERYCALCIFICATIONS INHEMODIALYSISPTS W/SECONDARYHYPERPARATHYROIDISM$12,455
M01 · FY2007 · RR · contact PI
CORONARYARTERYCALCIFICATIONS INHEMODIALYSISPTS W/SECONDARYHYPERPARATHYROIDISM$15,781
M01 · FY2006 · RR · contact PI
CORONARYARTERYCALCIFICATIONS INHEMODIALYSISPTS W/SECONDARYHYPERPARATHYROIDISM$858
M01 · FY2005 · RR